文献速递MDS 与骨髓增殖性肿瘤

年轻骨髓增殖性肿瘤患者的临床与遗传特征

[Clinical and genetic characteristics of young patients with myeloproliferative neoplasms].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

该横断面研究在全国范围内向骨髓增殖性肿瘤(MPN)患者发放问卷,按诊断时年龄分为年轻组(≤40岁)、中年组(41~60岁)和老年组(>60岁),比较三组的临床与基因突变特征。共收集1727份可分析问卷,年轻组453例(26.2%),包括ET 274例、PV 80例、MF 99例。年轻MPN患者具有独特的临床表现和基因突变特征。

要点

  • 年轻组(≤40岁)占26.2%(453/1727),包括ET 274例、PV 80例、MF 99例。
  • 年轻组未婚、高学历、无合并症、无合并用药、较低危险度分层占比较中老年组高(均P<0.001)。
  • 年轻组JAK2突变比例最低、CALR突变比例最高,非驱动基因突变和高分子风险突变检出率均最低。

核心结论

  • 与中年和老年MPN患者相比,年轻MPN患者具有独特的临床表现和基因突变特征。

研究设计与样本

  • 横断面研究,在全国范围内向MPN患者发放匿名问卷,共收集1727份可分析问卷。
  • 按诊断时年龄分为年轻组(≤40岁)、中年组(41~60岁)和老年组(>60岁),在各疾病类型中比较三组差异。

主要发现

  • 年轻组453例(26.2%),包括ET 274例、PV 80例、MF 99例(原发性MF 45例、PV后MF 20例、ET后MF 34例),男性178例(39.3%),中位年龄31(18~40)岁。
  • 与中年、老年受访者相比,年轻MPN受访者中未婚、高学历、无合并症、无合并用药、较低危险度分层占比较高(均P<0.001)。
  • 年轻MPN受访者以头痛为首发症状占比较高(ET:P<0.001;PV:P=0.007;MF:P=0.001),脾大比例在初诊(PV:P<0.001)和调研时(ET:P=0.052;PV:P=0.063)最高,血栓事件发生率在初诊(ET:P<0.001;PV:P=0.011)和调研时(ET:P<0.001;PV:P=0.003)均最低。
  • 年轻MPN受访者JAK2突变比例最低(ET:P<0.001;PV:P<0.001;MF:P=0.013),CALR突变比例最高(ET:P<0.001;MF:P=0.015),非驱动基因突变(ET:P=0.042;PV:P=0.043;MF:P=0.004)和高分子风险(HMR)突变(ET:P=0.024;PV:P=0.023;MF:P=0.001)检出率均最低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives: To investigate the clinical and genetic features of young Chinese patients with myeloproliferative neoplasms (MPN). Methods: In this cross-sectional study, anonymous questionnaires were distributed to patients with MPN patients nationwide. The respondents were divided into 3 groups based on their age at diagnosis: young (≤40 years) , middle-aged (41-60 years) , and elderly (>60 years) . We compared the clinical and genetic characteristics of three groups of MPN patients. Results: 1727 assessable questionnaires were collected. There were 453 (26.2%) young respondents with MPNs, including 274 with essential thrombocythemia (ET) , 80 with polycythemia vera (PV) , and 99 with myelofibrosis. Among the young group, 178 (39.3%) were male, and the median age was 31 (18-40) years. In comparison to middle-aged and elderly respondents, young respondents with MPN were more likely to present with a higher proportion of unmarried status (all P<0.001) , a higher education level (all P<0.001) , less comorbidity (ies) , fewer medications (all P<0.001) , and low-risk stratification (all P<0.001) . Younger respondents experienced headache (ET, P<0.001; PV, P=0.007; MF, P=0.001) at diagnosis, had splenomegaly at diagnosis (PV, P<0.001) , and survey (ET, P=0.052; PV, P=0.063) . Younger respondents had fewer thrombotic events at diagnosis (ET, P<0.001; PV, P=0.011) and during the survey (ET, P<0.001; PV, P=0.003) . JAK2 mutations were found in fewer young people (ET, P<0.001; PV, P<0.001; MF, P=0.013) ; however, CALR mutations were found in more young people (ET, P<0.001; MF, P=0.015) . Furthermore, mutations in non-driver genes (ET, P=0.042; PV, P=0.043; MF, P=0.004) and high-molecular risk mutations (ET, P=0.024; PV, P=0.023; MF, P=0.001) were found in fewer young respondents. Conclusion: Compared with middle-aged and elderly patients, young patients with MPN had unique clinical and genetic characteristics. 目的: 探究中国年轻骨髓增殖性肿瘤(MPN)患者的临床和基因突变特征。 方法: 通过横断面研究,在全国范围内向MPN患者发放调查问卷,根据诊断时年龄分为年轻组(≤40岁)、中年组(41~60岁)和老年组(>60岁),在各疾病类型中比较三组的差异。 结果: 共收集到1 727份可供分析的问卷,其中年轻组453例(26.2%),包括原发性血小板增多症(ET)274例、真性红细胞增多症(PV)80例、骨髓纤维化(MF)99例(原发性MF 45例,PV后MF 20例,ET后MF 34例);男性178例(39.3%),中位年龄31(18~40)岁。与中年、老年MPN受访者相比,年轻MPN受访者中未婚、高学历、无合并症、无合并用药、较低危险度分层占比较高(P<0.001)。年轻MPN受访者中以头痛为首发症状患者占比较高(ET:P<0.001;PV:P=0.007;MF:P=0.001),脾大的比例在初诊(PV:P<0.001)和调研时(ET:P=0.052;PV:P=0.063)最高,而血栓事件的发生率在初诊(ET:P<0.001;PV:P=0.011)和调研时(ET:P<0.001;PV:P=0.003)均最低。年轻MPN受访者JAK2突变比例最低(ET:P<0.001;PV:P<0.001;MF:P=0.013),CALR突变比例最高(ET:P<0.001;MF:P=0.015),非驱动基因突变(ET:P=0.042;PV:P=0.043;MF:P=0.004)和高分子风险(HMR)突变(ET:P=0.024;PV:P=0.023;MF:P=0.001)的检出率均最低。 结论: 与中、老年患者相比,年轻MPN患者有着特有的临床表现和基因突变特征。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang MY, Bao M, Shi DY, et al. [Clinical and genetic characteristics of young patients with myeloproliferative neoplasms]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37356980. doi:10.3760/cma.j.issn.0253-2727.2023.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。